Clavimox 1 g 8 tablets

Clavimox 1 g 8 tablets

Composition:
Each tablet contains:
Amoxicillin 875mg
Clavulanic acid 125mg
Auxiliary components:
Colloidal silicon dioxide, crospovidone, croscarmellose sodium, magnesium stearate, microcrystalline cellulose.
The composition of the film shell:
Hypromellose, ethyl cellulose, polysorbate 80, triethyl citrate, titanium dioxide, talc.
Properties:
Combined preparation of amoxicillin and clavulanic acid – a beta-lactamase inhibitor.
Acts bactericidal, inhibits the synthesis of the bacterial wall. Active against aerobic gram-positive bacteria (including strains producing beta-lactamase): Staphylococcus aureus; aerobic gram-negative bacteria: Enterobacter spp., Escherichia coli, Haemophilus influenzae, Klebsiella spp., Moraxella catarrhalis. The following pathogens are sensitive only in vitro: Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus anthracis, Streptococcus pneumoniae, Streptococcus viridans, Enterococcus faecalis, Corynebacterium spp., Listeria monocytogenes; anaerobic Clostridium spp., Peptococcus spp., Peptostreptococcus spp.; as well as aerobic gram-negative bacteria (including strains that produce beta-lactamases): Proteus mirabilis, Proteus vulgaris, Salmonella spp., Shigella spp., Bordetella pertussis, Yersinia enterocolitica, Gardnerella vaginalis, Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus ducreyi, Yersinia multocida (formerly Pasteurella), Campylobacter jejuni; anaerobic gram-negative bacteria (including strains producing beta-lactamases): Bacteroides spp., including Bacteroides fragilis.
Clavulanic acid inhibits types II, III, IV and V beta-lactamases, is inactive against type I beta-lactamases produced by Pseudomonas aeruginosa, Serratia spp., Acinetobacter spp.
Clavulanic acid has a high tropism for penicillinases, due to which it forms a stable complex with the enzyme, which prevents the enzymatic degradation of amoxicillin under the influence of beta-lactamases.
Indications: 
Treatment of infectious-inflammatory diseases caused by susceptible pathogens:
Lower respiratory tract infections (bronchitis, pneumonia, pleural empyema, lung abscess).
ENT infections (sinusitis, tonsillitis, otitis media).
Genitourinary and pelvic infections (pyelonephritis, pyelitis, cystitis, urethritis, prostatitis, cervicitis, salpingitis, salpingo-oophoritis, tubo-ovarian abscess, endometritis, bacterial vaginitis, septic abortion, postpartum sepsis, pelvic peritonitis, chancroid, gonorrhea).
Skin and soft tissue infections (erysipelas, impetigo, secondary infected dermatoses, abscess, phlegmon, wound infection).
Osteomyelitis.
Postoperative infections.
Infection prophylaxis in surgery.
Method of administration and dosage:
Adults and children over 12 years old or weighing 40 kg or more:
500 mg 2 times/day or 250 mg 3 times/day.
For severe infections and respiratory tract infections – 875 mg 2 times/day or 500 mg 3 times/day.
The maximum daily dose of amoxicillin for adults and children over 12 years old is 6 g, for children under 12 years old – 45 mg/kg body weight.
The maximum daily dose of clavulanic acid for adults and children over 12 years old is 600 mg, for children under 12 years old – 10 mg/kg body weight.
Duration of treatment up to 14 days, acute otitis media – up to 10 days.
Contraindications:
Hypersensitivity to the components of the drug (including cephalosporins and other beta-lactam antibiotics).
Infectious mononucleosis (including when a measles-like rash appears).
Phenylketonuria.
Episodes of jaundice or abnormal liver function as a result of amoxicillin/clavulanic acid use in history.
Creatinine clearance less than 30 ml/min (for tablets 875 mg/125 mg).
Carefully:
Pregnancy, lactation period, severe liver failure, gastrointestinal diseases (including a history of colitis associated with the use of penicillins), chronic renal failure.
Precautions:
During the course of treatment, it is necessary to monitor the function of hematopoietic organs, liver, and kidneys.
To reduce the risk of gastrointestinal side effects, the drug should be taken with meals.
The development of superinfection is possible due to the growth of microflora insensitive to the drug, which requires corresponding changes in antibacterial therapy. May give false positive results for urine glucose.
In this case, it is recommended to use the glucose oxidase method for determining glucose concentration in urine.
In patients with hypersensitivity to penicillins, cross-allergic reactions with cephalosporin antibiotics are possible.
Side effects:
From the digestive system: nausea, vomiting, diarrhea, gastritis, stomatitis, glossitis, increased activity of hepatic transaminases, in isolated cases – cholestatic jaundice, hepatitis, liver failure (more often in the elderly, men, with prolonged therapy), pseudomembranous and hemorrhagic colitis (can also develop after therapy), enterocolitis, black “hairy” tongue, darkening of tooth enamel.
From the hematopoietic system: reversible increase in prothrombin time and bleeding time, thrombocytopenia, thrombocytosis, eosinophilia, leukopenia, agranulocytosis, hemolytic anemia.
From the nervous system: dizziness, headache, hyperactivity, anxiety, changes in behavior, seizures.
Allergic reactions: urticaria, erythematous rash, rarely – exudative erythema multiforme, anaphylactic shock, angioedema, extremely rarely – exfoliative dermatitis, malignant exudative erythema (Stevens-Johnson syndrome), serous allergic vasculitis, pustular syndrome similar to acute exanthematous conditions.
Others: candidiasis, development of superinfection, interstitial nephritis, crystalluria, hematuria.
Storage method:
At a temperature not higher than 25°C.
Packaging:
The cardboard box contains 2 blisters of 4 tablets each, with paper instructions.